Royalty Pharma
Price
Price
Historical dividends and forecast
Royalty Pharma has so far distributed $0.63 in 2024. The next dividend will be paid on 10.12.2024
CHART BY
Frequently asked questions
What is Royalty Pharma's market capitalization?
What is Royalty Pharma's Price-to-Earnings (P/E) ratio?
What is the Earnings Per Share (EPS) for Royalty Pharma?
What are the analyst ratings and target price for Royalty Pharma's stock?
What is Royalty Pharma's revenue over the trailing twelve months?
Is Royalty Pharma paying dividends?
What is the EBITDA for Royalty Pharma?
What is the free cash flow of Royalty Pharma?
What is the 5-year beta of Royalty Pharma's stock?
How many employees does Royalty Pharma have, and what sector and industry does it belong to?
What is the free float of Royalty Pharma's shares?
Financials
Market Cap
$15.55B5Y beta
0.46EPS (TTM)
$2.558Free Float
380.91MP/E ratio (TTM)
10.32Revenue (TTM)
$2.27BEBITDA (TTM)
$1.54BFree Cashflow (TTM)
-$584.58MPricing
Analyst Ratings
The price target is $44.50 and the stock is covered by 8 analysts.
Buy
6
Hold
2
Sell
0
Information
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Ecopipam, Olpasiran, Pelabresib, KarXT, Pelacarsen, Seltorexant, Trontinemab, TEV-'749, Tulmimetostat and Vanzacaftor. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.
89
Misc. Financial Services
Health Care
Identifier
ISIN
Primary Ticker